175 related articles for article (PubMed ID: 11705991)
1. MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA.
Zdraveski ZZ; Mello JA; Farinelli CK; Essigmann JM; Marinus MG
J Biol Chem; 2002 Jan; 277(2):1255-60. PubMed ID: 11705991
[TBL] [Abstract][Full Text] [Related]
2. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
[TBL] [Abstract][Full Text] [Related]
3. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
4. MutS inhibits RecA-mediated strand exchange with platinated DNA substrates.
Calmann MA; Marinus MG
Proc Natl Acad Sci U S A; 2004 Sep; 101(39):14174-9. PubMed ID: 15375217
[TBL] [Abstract][Full Text] [Related]
5. Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells.
Nehmé A; Baskaran R; Nebel S; Fink D; Howell SB; Wang JY; Christen RD
Br J Cancer; 1999 Mar; 79(7-8):1104-10. PubMed ID: 10098743
[TBL] [Abstract][Full Text] [Related]
6. Binding discrimination of MutS to a set of lesions and compound lesions (base damage and mismatch) reveals its potential role as a cisplatin-damaged DNA sensing protein.
Fourrier L; Brooks P; Malinge JM
J Biol Chem; 2003 Jun; 278(23):21267-75. PubMed ID: 12654906
[TBL] [Abstract][Full Text] [Related]
7. Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells.
Gibbons GR; Kaufmann WK; Chaney SG
Carcinogenesis; 1991 Dec; 12(12):2253-7. PubMed ID: 1747924
[TBL] [Abstract][Full Text] [Related]
8. Specificity of platinum-DNA adduct repair.
Chaney SG; Vaisman A
J Inorg Biochem; 1999 Oct; 77(1-2):71-81. PubMed ID: 10626357
[TBL] [Abstract][Full Text] [Related]
9. Monofunctional platinum-DNA adducts are strong inhibitors of transcription and substrates for nucleotide excision repair in live mammalian cells.
Zhu G; Myint M; Ang WH; Song L; Lippard SJ
Cancer Res; 2012 Feb; 72(3):790-800. PubMed ID: 22180496
[TBL] [Abstract][Full Text] [Related]
10. Protein interactions with platinum-DNA adducts: from structure to function.
Chaney SG; Campbell SL; Temple B; Bassett E; Wu Y; Faldu M
J Inorg Biochem; 2004 Oct; 98(10):1551-9. PubMed ID: 15458816
[TBL] [Abstract][Full Text] [Related]
11. Role of carrier ligand in platinum resistance in L1210 cells.
Gibbons GR; Page JD; Mauldin SK; Husain I; Chaney SG
Cancer Res; 1990 Oct; 50(20):6497-501. PubMed ID: 2208108
[TBL] [Abstract][Full Text] [Related]
12. The role of DNA mismatch repair in platinum drug resistance.
Fink D; Nebel S; Aebi S; Zheng H; Cenni B; Nehmé A; Christen RD; Howell SB
Cancer Res; 1996 Nov; 56(21):4881-6. PubMed ID: 8895738
[TBL] [Abstract][Full Text] [Related]
13. The MutS C terminus is essential for mismatch repair activity in vivo.
Calmann MA; Nowosielska A; Marinus MG
J Bacteriol; 2005 Sep; 187(18):6577-9. PubMed ID: 16159793
[TBL] [Abstract][Full Text] [Related]
14. MutS recognition of exocyclic DNA adducts that are endogenous products of lipid oxidation.
Johnson KA; Mierzwa ML; Fink SP; Marnett LJ
J Biol Chem; 1999 Sep; 274(38):27112-8. PubMed ID: 10480926
[TBL] [Abstract][Full Text] [Related]
15. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin.
Mello JA; Acharya S; Fishel R; Essigmann JM
Chem Biol; 1996 Jul; 3(7):579-89. PubMed ID: 8807890
[TBL] [Abstract][Full Text] [Related]
16. Transcription inhibition by platinum-DNA cross-links in live mammalian cells.
Ang WH; Myint M; Lippard SJ
J Am Chem Soc; 2010 Jun; 132(21):7429-35. PubMed ID: 20443565
[TBL] [Abstract][Full Text] [Related]
17. Cellular and molecular aspects of drugs of the future: oxaliplatin.
Di Francesco AM; Ruggiero A; Riccardi R
Cell Mol Life Sci; 2002 Nov; 59(11):1914-27. PubMed ID: 12530522
[TBL] [Abstract][Full Text] [Related]
18. Debio 0507 primarily forms diaminocyclohexane-Pt-d(GpG) and -d(ApG) DNA adducts in HCT116 cells.
King CL; Ramachandran S; Chaney SG; Collins L; Swenberg JA; DeKrafft KE; Lin W; Cicurel L; Barbier M
Cancer Chemother Pharmacol; 2012 Mar; 69(3):665-77. PubMed ID: 21968950
[TBL] [Abstract][Full Text] [Related]
19. The molecular mechanism of DNA damage recognition by MutS homologs and its consequences for cell death response.
Salsbury FR; Clodfelter JE; Gentry MB; Hollis T; Scarpinato KD
Nucleic Acids Res; 2006; 34(8):2173-85. PubMed ID: 16648361
[TBL] [Abstract][Full Text] [Related]
20. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts.
Chaney SG; Campbell SL; Bassett E; Wu Y
Crit Rev Oncol Hematol; 2005 Jan; 53(1):3-11. PubMed ID: 15607931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
